| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Marco Maria Brughera is Director at SNGX and has filed Form 4s across 2 companies. Marco Maria Brughera's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $979 at current prices.
The biggest single holding is SNGX (~$979) as Director. Net of sales, the SNGX filings show accumulation of 2,000 shares.
Marco Maria Brughera has 14 Form 4 filings on record from June 2015 to September 2026, across 2 companies: Director at Fennec Pharmaceuticals (FENC), 2018–2026; Director at Soligenix (SNGX), 2015–2017.
The 16 reported transactions were 12 option or other derivative awards, 2 open-market purchases, 1 option exercise and 1 open-market sale.
Counted by filing, the open-market trades come to 1 purchase worth about $6K and 1 sale worth about $160K.
The only open-market purchase was 2,000 shares of SNGX at an average $3.16 on December 16, 2016, about $6K.
The only open-market sale was 15,545 shares of FENC at an average $10.29 on September 15, 2026, about $160K.